A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Cabiralizumab (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 18 Dec 2017 Planned End Date changed from 1 Mar 2020 to 15 Dec 2020.
- 18 Dec 2017 Planned primary completion date changed from 1 Mar 2020 to 14 Dec 2020.
- 18 Dec 2017 Status changed from not yet recruiting to recruiting.